IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

Jun

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun

Featured Webinar

Menu

IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Guardant Health Prices $319.5M Public Stock Offering

Biocept Targets Pathologists, Naturopaths to Drive Liquid Biopsy Adoption

Sponsorships